The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Another interesting and exciting challenge study win for our (very) undervalued company, this time with income being recognised in 2023 thus strengthening our future prospects. Nice one (again) Mo.
Booom, 20p by lunchtime.
No? Okay then. Onwards we go with one more arrow in the quiver. One day.... ;)
Excellent news and just what we wanted to hear right now :)
I did say last week we're probably not far of Covid contracts, well here's to many more...GLA...oh and bye the way Mo cannot buy whilst all these contracts are being negotiated.. so stop moaning...lol
Somebody obviously got wind of it late yesterday with a nice little 250k purchase at the close?
12p everyone…. 12p
Well it speaks to the fact that Mo is CEO. Still don’t get the CF haters, company keeps delivering contracts, keeps up groundbreaking R&D. Some serious data will flow from Covid studies like this one. Timelines may have shifted - name me a company where timelines don’t shift- but OO still has a unique and lucrative role to play in what, come winter, will no doubt look like an ongoing existential challenge for health services across the world. It is estimated that there are 250 anti-Covis drugs and vaccines in development. More than a few will take notice of this imho
Last nights sneaky buyer should have waited - cheaper this morning lol.
These anonymous Keyboard warriors can criticise all they like but CF has created the opportunity for Mo to execute CF's plan...I would suggest some of these CF bashers take a reality check!..CF has beefed up the the financial positions of OO and allowed to company to expand even more than anyone could have dreamed of 2 years ago..income could easily double in the next couple of years judging by the amount of new contracts rolling in...a lot more to come from OO I believe. Aimho Adyor!
Ah yet another new poster with 26 posts coming out of the woodwork..how much are they paying you guys to bash the company????
Jazza, Cathal said some time ago that they would not be issuing RNSs for small contracts. I seem to recall he said that would be anything under 1m so i draw the conclusion that this is over that Or it is strategically important tot he company. Either way, it's excellent news
Here’s a handy cut out and keep guide for the hard of thinking JG: https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm
Exec summary: covid is significantly more contagious, and demonstrably more lethal than flu, with longer lasting consequences. Less is known about it. It retains the capacity to quickly overwhelm health services and economies.anything else you need to know?
It a waste of time trying to explain anything to these new trolls..they have a clear agenda that is to discredit CF and creative negativity all the time..all we can do is keep a positive perspective and don't get sucked into negative threads created by these guys. Nothing wrong with the odd criticism but these guys are taking to another level for obvious reasons...
I have not used a green bin in a long while. Been far too busy for months but here we go
There's so many of these new trolls, all I can see is loads of green boxes now...very annoying...it's getting worse than the ADVFN board..
Another green box...that's 9 already this morning now that I've added jazzman to the list of paid trolls....GLA a d keep posting the positive news coming from OO..
From an investor point of view... does it f*cking matter which is more dangerous? ORPH are the leaders in both Flu and Covid trials :-)
11 green boxes...= sad loser.. stop crying and get a job at the checkout.
I note that people keep going on about the mystery 100k seller, but no mention of the 250k buyer that has appeared twice now since yesterday?
And another 150,000
I don’t think that we need to worry too much about the immediate income that would arise from the development of the challenge study model itself. The major income would come from the clinical testing of the vaccine .
What is also very important is that Mo has said that there are other biopharm companies already expressing an interest in trials.
Accommodation for such trials shouldn’t be a problem as he said in a recent presentation that a team exists to identify suitable sites and that these could become ready for use within the necessary time frame.
All looking good!
Always pays to read to the end JG: "COVID spreads a lot faster and more easily than the flu, meaning that it can still produce a lot more infections. Two viruses may be equally lethal on an individual level, but if one infects a lot more individuals, it will kill a lot more individuals. A small percentage of a really big number is still a big number. That largely explains why this winter’s overall death toll in England from respiratory illness was still 50 percent higher than during a typical flu season.
House broker still reiterating 44p SP target, something has to give with all this good news coming in. ..........FY 2022 forecasts unchanged and reiterate our 44p target price.....
Timely contract as WHO concerned over global rise in Covid cases...
https://news.sky.com/story/covid-infections-rise-in-110-countries-as-whos-director-general-warns-pandemic-is-far-from-over-12643440